HY-143890 Search Results


sting agonist  (MedChemExpress)
90
MedChemExpress sting agonist
A . Concentrated protein (> 3 kDa) and metabolites (< 3 kDa) in tumor conditional media (TCM) were separated by protein concentrator (left). Quantitative PCR mRNA expression analysis of bone marrow-derived macrophages (BMDMs) treated with different fraction of TCM ± vehicle or GB1275 for 7 h. Changes in gene expressions are depicted as the fold change from the vehicle baseline (right). B . Cytochrome C released in metabolites (< 3 kDa) from either normal media or TCM (< 3 kDa) made from KP2 cell lines treated with 10 μM gemcitabine or vehicle for 8 h, was detected by quantitative PCR analyses. Changes in gene expression are depicted as the fold change from TCM group baseline. C . Quantitative PCR mRNA expression analysis of BMDMs treated with metabolite of TCM (< 3 kDa) in the presence or absence of ethidium bromide + vehicle or GB1275 for 7 h. Changes in gene expressions are depicted as the fold change from the vehicle baseline. D . KP2 cells were treated with either 10 μM gemcitabine or 8 Gy radiation. After 8 h, the cells were rinsed with phosphate-buffered saline, and incubated with medium containing 1% fetal bovine serum to make TCM (left). Quantitative PCR mRNA expression analysis of BMDMs treated with the abovementioned TCM ± Vehicle or GB1275 for 7 h. Changes in gene expression are depicted as the fold changes from the vehicle baseline. E . Syngeneic tumor growth of KP2 cells in mice treated with vehicle or GB1275 (120mg/kg) ± chemotherapy (50 mg/kg gemcitabine + 10 mg/kg paclitaxel) (left). Mean percent change in tumor volume is shown 12 days after treatment (n = 9–10/group) (middle). (right) Kaplan-Meier survival analysis of mice in these four groups (n = 9–10/group). F . Quantitative PCR mRNA expression analysis of tissue from E (n = 6-8 group). Changes in gene expressions are depicted as the fold changes from the vehicle baseline. G . Syngeneic tumor growth of KP2 cells in mice treated with vehicle or GB1275 (120mg/kg) ± radiation therapy (6 Gy × 5) in the presence or absence <t>of</t> <t>ADU-S100</t> (1.25 mg/kg) (left). Mean percent change in tumor volume is shown 12 days after treatment (n = 10/group) (left). (right) Kaplan-Meier survival analyses of mice in these five groups (n =10/group). The graphs show the mean ± SEM; *denotes p < 0.05 using the two-sided t- test, analysis of variance, or log-rank test. In vitro data are representative of three independent experiments.
Sting Agonist, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sting agonist/product/MedChemExpress
Average 90 stars, based on 1 article reviews
sting agonist - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier

Image Search Results


A . Concentrated protein (> 3 kDa) and metabolites (< 3 kDa) in tumor conditional media (TCM) were separated by protein concentrator (left). Quantitative PCR mRNA expression analysis of bone marrow-derived macrophages (BMDMs) treated with different fraction of TCM ± vehicle or GB1275 for 7 h. Changes in gene expressions are depicted as the fold change from the vehicle baseline (right). B . Cytochrome C released in metabolites (< 3 kDa) from either normal media or TCM (< 3 kDa) made from KP2 cell lines treated with 10 μM gemcitabine or vehicle for 8 h, was detected by quantitative PCR analyses. Changes in gene expression are depicted as the fold change from TCM group baseline. C . Quantitative PCR mRNA expression analysis of BMDMs treated with metabolite of TCM (< 3 kDa) in the presence or absence of ethidium bromide + vehicle or GB1275 for 7 h. Changes in gene expressions are depicted as the fold change from the vehicle baseline. D . KP2 cells were treated with either 10 μM gemcitabine or 8 Gy radiation. After 8 h, the cells were rinsed with phosphate-buffered saline, and incubated with medium containing 1% fetal bovine serum to make TCM (left). Quantitative PCR mRNA expression analysis of BMDMs treated with the abovementioned TCM ± Vehicle or GB1275 for 7 h. Changes in gene expression are depicted as the fold changes from the vehicle baseline. E . Syngeneic tumor growth of KP2 cells in mice treated with vehicle or GB1275 (120mg/kg) ± chemotherapy (50 mg/kg gemcitabine + 10 mg/kg paclitaxel) (left). Mean percent change in tumor volume is shown 12 days after treatment (n = 9–10/group) (middle). (right) Kaplan-Meier survival analysis of mice in these four groups (n = 9–10/group). F . Quantitative PCR mRNA expression analysis of tissue from E (n = 6-8 group). Changes in gene expressions are depicted as the fold changes from the vehicle baseline. G . Syngeneic tumor growth of KP2 cells in mice treated with vehicle or GB1275 (120mg/kg) ± radiation therapy (6 Gy × 5) in the presence or absence of ADU-S100 (1.25 mg/kg) (left). Mean percent change in tumor volume is shown 12 days after treatment (n = 10/group) (left). (right) Kaplan-Meier survival analyses of mice in these five groups (n =10/group). The graphs show the mean ± SEM; *denotes p < 0.05 using the two-sided t- test, analysis of variance, or log-rank test. In vitro data are representative of three independent experiments.

Journal: bioRxiv

Article Title: Context-dependent triggering of STING-interferon signaling by CD11b agonists supports anti-tumor immunity in mouse models and human cancer patients

doi: 10.1101/2022.03.22.485233

Figure Lengend Snippet: A . Concentrated protein (> 3 kDa) and metabolites (< 3 kDa) in tumor conditional media (TCM) were separated by protein concentrator (left). Quantitative PCR mRNA expression analysis of bone marrow-derived macrophages (BMDMs) treated with different fraction of TCM ± vehicle or GB1275 for 7 h. Changes in gene expressions are depicted as the fold change from the vehicle baseline (right). B . Cytochrome C released in metabolites (< 3 kDa) from either normal media or TCM (< 3 kDa) made from KP2 cell lines treated with 10 μM gemcitabine or vehicle for 8 h, was detected by quantitative PCR analyses. Changes in gene expression are depicted as the fold change from TCM group baseline. C . Quantitative PCR mRNA expression analysis of BMDMs treated with metabolite of TCM (< 3 kDa) in the presence or absence of ethidium bromide + vehicle or GB1275 for 7 h. Changes in gene expressions are depicted as the fold change from the vehicle baseline. D . KP2 cells were treated with either 10 μM gemcitabine or 8 Gy radiation. After 8 h, the cells were rinsed with phosphate-buffered saline, and incubated with medium containing 1% fetal bovine serum to make TCM (left). Quantitative PCR mRNA expression analysis of BMDMs treated with the abovementioned TCM ± Vehicle or GB1275 for 7 h. Changes in gene expression are depicted as the fold changes from the vehicle baseline. E . Syngeneic tumor growth of KP2 cells in mice treated with vehicle or GB1275 (120mg/kg) ± chemotherapy (50 mg/kg gemcitabine + 10 mg/kg paclitaxel) (left). Mean percent change in tumor volume is shown 12 days after treatment (n = 9–10/group) (middle). (right) Kaplan-Meier survival analysis of mice in these four groups (n = 9–10/group). F . Quantitative PCR mRNA expression analysis of tissue from E (n = 6-8 group). Changes in gene expressions are depicted as the fold changes from the vehicle baseline. G . Syngeneic tumor growth of KP2 cells in mice treated with vehicle or GB1275 (120mg/kg) ± radiation therapy (6 Gy × 5) in the presence or absence of ADU-S100 (1.25 mg/kg) (left). Mean percent change in tumor volume is shown 12 days after treatment (n = 10/group) (left). (right) Kaplan-Meier survival analyses of mice in these five groups (n =10/group). The graphs show the mean ± SEM; *denotes p < 0.05 using the two-sided t- test, analysis of variance, or log-rank test. In vitro data are representative of three independent experiments.

Article Snippet: STING agonist (ADU-S100) was purchased from MedChemExpress (Monmouth Junction, NJ, USA) and was administered at 1.25 mg/kg by intertumoral injections every 4 days.

Techniques: Real-time Polymerase Chain Reaction, Expressing, Derivative Assay, Saline, Incubation, In Vitro

A . Tumor burden from the KP2 syngeneic mouse model treated with vehicle or GB1275 (120mg/kg) ± ADU-S100 (1.25 mg/kg) for 19 days (n = 10/group) shown by tumor volume. B . Relative frequencies of tumor infiltrating CD8 + T cells and macrophages from the above mice (n = 6/group). C . Immunohistochemical staining for CD8 + T cells in tumors from 14-day vehicle and GB1275 (120mg/kg)-treated KPPC mice. Scale bar, 100 μm. Average percentage of CD8 + T cells from each treatment group (n = 6−7/group) (right). D . Syngeneic model of KP2 treated with GB1275 (120mg/kg), ADU-S100 (1.25 mg/kg), or the combination of GB1275 and ADU-S100 for 14 days (left). CyTOF UMAP plot of tumor infiltrating T cells, including of CD8 + T cells, Th, and T Regs from the above tissues (n = 6/group). E . Percentages of individual subclusters in CD8 + T cells from three groups. F . Median expressions of GZB, PD-1, and CTLA-4 in CD8 + T cells. G . CyTOF UMAP plot of tumor infiltrating myeloid cells, including tumor-associated macrophages (TAMs), granulocytes, monocytes, and dendritic cells from the above tissues (n = 6/group). H . Percentage of individual subclusters in TAMs from three groups. Graphs show the mean ± SEM; *denotes P < 0.05 using the two-sided t -test or analysis of variance.

Journal: bioRxiv

Article Title: Context-dependent triggering of STING-interferon signaling by CD11b agonists supports anti-tumor immunity in mouse models and human cancer patients

doi: 10.1101/2022.03.22.485233

Figure Lengend Snippet: A . Tumor burden from the KP2 syngeneic mouse model treated with vehicle or GB1275 (120mg/kg) ± ADU-S100 (1.25 mg/kg) for 19 days (n = 10/group) shown by tumor volume. B . Relative frequencies of tumor infiltrating CD8 + T cells and macrophages from the above mice (n = 6/group). C . Immunohistochemical staining for CD8 + T cells in tumors from 14-day vehicle and GB1275 (120mg/kg)-treated KPPC mice. Scale bar, 100 μm. Average percentage of CD8 + T cells from each treatment group (n = 6−7/group) (right). D . Syngeneic model of KP2 treated with GB1275 (120mg/kg), ADU-S100 (1.25 mg/kg), or the combination of GB1275 and ADU-S100 for 14 days (left). CyTOF UMAP plot of tumor infiltrating T cells, including of CD8 + T cells, Th, and T Regs from the above tissues (n = 6/group). E . Percentages of individual subclusters in CD8 + T cells from three groups. F . Median expressions of GZB, PD-1, and CTLA-4 in CD8 + T cells. G . CyTOF UMAP plot of tumor infiltrating myeloid cells, including tumor-associated macrophages (TAMs), granulocytes, monocytes, and dendritic cells from the above tissues (n = 6/group). H . Percentage of individual subclusters in TAMs from three groups. Graphs show the mean ± SEM; *denotes P < 0.05 using the two-sided t -test or analysis of variance.

Article Snippet: STING agonist (ADU-S100) was purchased from MedChemExpress (Monmouth Junction, NJ, USA) and was administered at 1.25 mg/kg by intertumoral injections every 4 days.

Techniques: Immunohistochemical staining, Staining